Our data in Figs. 5–7 show that severing the BACE2 dose by a third, using CRISPR/Cas9, might tip the balance against the anti-amyloidogenic activity, and provoke AD-like pathology. The gene discussed is BACE2; the disease is Alzheimer disease.